Clinical Research Directory
Browse clinical research sites, groups, and studies.
Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Sponsor: Tanta University
Summary
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
Official title: Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Key Details
Gender
All
Age Range
45 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-05-10
Completion Date
2026-05-30
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
levodopa-carbidopa
Carbidopa/levodopa is a combination of two medications: carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease. The main and most effective treatment strategy for motor symptoms in Parkinson's disease relies on replenishing dopamine levels through the use of L-dopa.
Silymarin
Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, is employed clinically for managing hepatic disorders. Its antioxidant effects are primarily attributed to its ability to scavenge free radicals.
Locations (1)
Tanta Hospital for Mental Health
Tanta, Tanta, Qism 2, Egypt